6/18/2020 12:30:52 PM - Perched at its all-time high today following volume-driven gains. It did not for a sound base pattern. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has FDA approved coronavirus tests. It has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following very strong earnings growth in FY &#39;17 and &#39;18.<br><hr>6/17/2020 12:58:48 PM - Hitting a new all-time high today. It did not for a sound base of sufficient length. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has FDA approved coronavirus tests. It has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following very strong earnings growth in FY &#39;17 and &#39;18.<br><hr>6/16/2020 1:04:06 PM - Rebounded near its all-time high but it did not for a sound base. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has FDA approved coronavirus tests. It has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following very strong earnings growth in FY &#39;17 and &#39;18.<br><hr>6/15/2020 12:30:09 PM - Rebounding near its all-time high but it did not for a sound base. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has FDA approved coronavirus tests. It has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following very strong earnings growth in FY &#39;17 and &#39;18.<br><hr>5/18/2020 12:44:13 PM - Pulling back from its high after getting very extended from any sound base with a considerable gap up on 5/11/20 following FDA approval of a new coronavirus test. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following very strong earnings growth in FY &#39;17 and &#39;18.<br><hr>5/15/2020 12:58:34 PM - Consolidating near its high after getting very extended from any sound base with a considerable gap up on 5/11/20 following FDA approval of a new coronavirus test. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following very strong earnings growth in FY &#39;17 and &#39;18.<br><hr>5/12/2020 12:30:26 PM - Pulling back today after getting very extended from any sound base with a considerable gap up on the prior session. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 96.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>5/11/2020 12:51:49 PM - Very extended from any sound base. Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 96.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>5/7/2020 1:41:52 PM - Reported Mar &#39;20 quarterly earnings +34% on +18% sales revenues versus the year ago period, and sequential comparisons show encouraging acceleration in its sales revenues growth rate. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 97.  Prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/28/2020 12:40:46 PM - Pulling back today after spiking to new all-time highs with 6 consecutive gains backed by volume conviction. Due to report earnings news on 5/06/20. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/27/2020 12:55:20 PM - Spiking to new all-time highs with recent gain backed by greater volume conviction. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/24/2020 12:50:04 PM - Spiked to new all-time highs with recent gain backed by greater volume conviction. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/22/2020 12:26:40 PM - Spiking to new all-time highs with recent gains lacking great volume conviction. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/20/2020 12:30:21 PM - Consolidating after spiking to a new all-time high with recent volume-driven gains. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/7/2020 12:25:28 PM - Consolidating after spiking to a new all-time high with recent volume-driven gains. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/6/2020 12:24:09 PM - Consolidating after spiking to a new all-time high with recent volume-driven gains. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>4/2/2020 12:42:24 PM - Consolidating after spiking to a new all-time high with 3 consecutive volume-driven gains. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>3/31/2020 12:26:47 PM - This San Diego, CA based maker of rapid diagnostic tests for infectious diseases reversed into the red today after spiking to a new all-time high with 3 consecutive volume-driven gains. It has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>3/30/2020 12:29:34 PM - This San Diego, CA based maker of rapid diagnostic tests for infectious diseases is challenging its all-time high with today&#39;s 3rd consecutive volume-driven gain. It has earned a high Earnings Per Share rating of 95.  Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>3/27/2020 12:43:41 PM - This San Diego, CA based maker of rapid diagnostic tests for infectious diseases is challenging its all-time high with today&#39;s 2nd consecutive volume-driven gain. Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY &#39;19 following strong earnings growth in FY &#39;17 and &#39;18.<br><hr>3/23/2020 12:46:24 PM - This San Diego, CA based maker of rapid diagnostic tests for infectious diseases is perched near its all-time high. Made a few mid-day report appearances last week noted with caution - <i>&quot;Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter. Prior quarterly and annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s fundamental guidelines.&quot;</i><br><hr>3/20/2020 1:05:18 PM - This San Diego, CA based maker of rapid diagnostic tests for infectious diseases is perched at its all-time high. Made 2 prior mid-day report appearances this week noted with caution - <i>&quot;Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter. Prior quarterly and annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s fundamental guidelines.&quot;</i><br><hr>3/17/2020 1:21:46 PM - This San Diego, CA based maker of rapid diagnostic tests for infectious diseases is perched at its all-time high and making its 2nd consecutive mid-day report appearance. Previously noted with caution - <i>&quot;Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter. Prior quarterly and annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s fundamental guidelines.&quot;</i><br><hr>3/16/2020 12:44:40 PM - Perched near its all-time high. Reported earnings +23% on +15% sales revenues for the Dec &#39;19 quarter. Prior quarterly and annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s fundamental guidelines.<br><hr>1/17/2020 12:54:06 PM - Encountering distributional pressure with a 3rd consecutive volume-driven loss. Reported earnings +17% on +8% sales revenues for the Sep &#39;19 quarter. Prior quarterly comparisons versus the year-ago period were negative. Went through a choppy consolidation since noted in the 11/07/18 mid-day report - <i>&quot;Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.&quot;</i><br><hr>1/16/2020 12:51:25 PM - Encountering distributional pressure with a 2nd consecutive volume-driven loss. Reported earnings +17% on +8% sales revenues for the Sep &#39;19 quarter. Prior quarterly comparisons versus the year-ago period were negative. Went through a choppy consolidation since noted in the 11/07/18 mid-day report - <i>&quot;Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.&quot;</i><br><hr>1/10/2020 1:02:22 PM - Reported earnings +17% on +8% sales revenues for the Sep &#39;19 quarter. Prior quarterly comparisons versus the year-ago period were negative. Went through a choppy consolidation since last noted in the 11/07/18 mid-day report - <i>&quot;Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.&quot;</i><br><hr>11/7/2018 1:30:53 PM - Reported earnings +247% on +131% sales revenues for the Sep &#39;18 quarter. Undercut its 200 DMA line today and then quickly rebounded near its 50 DMA line ($67.22) which has acted as resistance in recent weeks. Last noted in the 9/19/18 mid-day report - <i>&quot;Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.&quot;</i><br><hr>9/19/2018 12:41:33 PM - Pulling back from its all-time high and violating its 50 DMA line ($70.73) with today&#39;s loss. Noted in prior mid-day reports - <i>&quot;Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.&quot;</i><br><hr>8/30/2018 1:07:49 PM - Hitting a new all-time high today, getting more extended from any sound base. Found prompt support near its 50 DMA line since last noted in the 8/08/18 mid-day report - <i>&quot;Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.&quot;</i><br><hr>8/8/2018 1:07:50 PM - Perched at its all-time high, extended from any sound base. Showed strong sales revenues and earning increases in the Dec &#39;17, Mar and Jun &#39;18 quarters. Annual earnings (A criteria) history has been up and down, not a match with the fact-based system&#39;s guidelines.<br><hr>6/1/2018 1:00:32 PM - Perched at its all-time high, extended from any sound base. Showed strong sales revenues and earning increases in the Dec &#39;17 and Mar &#39;18 quarters. Prior earnings history has been erratic. Last noted in the 7/12/13 mid-day report - <em>&quot;Its quarterly and annual earnings (<strong>C</strong> and <strong>A</strong> criteria) history is not a match with the fact-based system&#39;s guidelines.&quot; </em><br><hr>7/12/2013 1:30:56 PM - Perched at its 52-week high after overcoming some distributional pressure. Showed strong sales revenues and earning increases in the Dec &#39;12 and Mar &#39;13 quarters, but prior earnings history has been erratic. Undercut its 200 DMA line when consolidating and then rebounded and rallied for new highs since last noted in the 4/05/12 mid-day report with caution - <em>&quot;Its quarterly and annual earnings (<strong>C</strong> and <strong>A</strong> criteria) history is not a match with the fact-based system&#39;s guidelines.&quot; </em><br><hr>4/5/2012 12:59:00 PM - Reached a new 52-week high this week and encountered some distributional pressure. Its quarterly and annual earnings (<strong>C</strong> and <strong>A</strong> criteria) history is not a match with the fact-based system&#39;s guidelines.<br><hr>7/25/2008 1:57:08 PM - Earnings and sales history below guidelines. Reached a new 52-week high today  following a considerable gain on 7/24/08 with heavy volume.<br><hr>7/24/2008 1:53:05 PM - Earnings and sales history below guidelines.<br><hr>11/7/2006 12:53:07 PM - "C" and sales history below guidelines.<br><hr>11/3/2006 12:49:13 PM - C and sales history below guidelines.<br><hr>11/25/2005 11:29:56 AM - C and sales history below guidelines.<br><hr>11/23/2005 1:00:24 PM - C and sales history below guidelines.<br><hr>11/22/2005 12:59:20 PM - C and sales history below guidelines.<br><hr>11/21/2005 1:02:25 PM - C and sales history below guidelines.<br><hr>11/18/2005 1:09:08 PM - C and sales history below guidelines.<br><hr>11/15/2005 1:32:20 PM - "C" and sales history below guidelines.<br><hr>11/14/2005 12:44:50 PM - "C" and sales history below guidelines.<br><hr>11/9/2005 12:45:48 PM - "C" and sales history below guidelines.<br><hr>11/7/2005 12:45:03 PM - "C" and sales history below guidelines.<br><hr>11/4/2005 12:35:12 PM - "C" and sales history below guidelines. No base.<br><hr>10/26/2005 1:56:44 PM - "C" and sales history poor. Too ET.<br><hr>10/21/2005 12:41:36 PM - "C" and sales history poor.<br><hr>10/7/2005 12:51:58 PM - "C" and sales history poor.<br><hr>10/6/2005 12:34:33 PM - "C" and sales history poor.<br><hr>9/26/2005 12:55:27 PM - "C" and sales history poor.<br><hr>9/6/2005 1:03:18 PM - "C" and sales history poor.<br><hr>8/18/2005 12:26:01 PM - "C" and sales history poor.<br><hr>8/1/2005 1:13:20 PM - "C" and sales history poor.<br><hr>7/28/2005 1:54:44 PM - "C" and sales history poor.<br><hr>7/19/2005 12:23:25 PM - "C" and sales history poor.<br><hr>